The best way forward is through powerful case-control studies in populations that have developed a COVID-19-related outcome (recovery/death) and/or in populations undergoing a COVID-19-related process (uninfected/infected and/or symptomatic/asymptomatic) by taking such persons as relative cases and controls, and evaluating the association with their ACE2 genotypes. This evidence concerns the gene ACE2 and COVID-19.